Lipase Sequence Variants for Higher Heterologous Expression

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Lipases from the Proteus/Yersinia clade face challenges in heterologous expression, limiting their industrial applicability and requiring low-cost manufacturing, despite their potential in various industrial applications due to substrate specificity variations.

Innovation Solution

Development of lipase mutants with specific amino acid substitutions at predetermined positions, enhancing heterologous expression and broadening sequence diversity for improved industrial use.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If lipases from Proteus/Yersinia clade are used for heterologous expression, then substrate specificity and cleansing performance are improved, but manufacturing cost increases due to low expression levels requiring chaperone co-expression

Engineering Contradiction:
Improvesubstrate specificityVSAvoidmanufacturing cost
Core Design Contradiction:
Adaptability or versatilityVSEase of manufacture

Solution Approach 1:

The patent applies parameter changes by modifying amino acid residues at specific positions (31, 32, 90, 181) in the lipase sequence to improve heterologous expression levels. These sequence modifications enable high-level expression without requiring chaperone co-expression, thereby reducing manufacturing costs while preserving the enzyme's substrate specificity and catalytic performance.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If chaperone co-expression is used to improve folding, then active form production is enhanced, but productivity decreases due to complex expression systems

Engineering Contradiction:
Improvefolding efficiencyVSAvoidproductivity
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent extracts the folding problem by directly modifying the lipase sequence to improve its intrinsic foldability and stability. This eliminates the need for chaperone co-expression systems, simplifying the expression system and improving productivity while maintaining reliable production of the active enzyme form.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The modified lipase sequences possess self-service capabilities for proper folding and stability without requiring external chaperone assistance. The amino acid modifications at key positions enable the enzyme to autonomously achieve its active conformation, streamlining the expression process.

Inventive Principle:
Principle #25Self-service

3Adaptability or versatility

If sequence diversity is broadened for different applications, then application versatility is improved, but screening complexity increases

Engineering Contradiction:
Improveapplication versatilityVSAvoidscreening complexity
Core Design Contradiction:
Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent creates universal lipase variants through targeted amino acid modifications that maintain broad substrate specificity across different applications. The modified sequences at positions 31, 32, 90, and 181 generate enzymes suitable for multiple uses including cleansing, optical resolution, biofuel manufacturing, and wastewater treatment, reducing the need for extensive screening of different lipase variants.

Inventive Principle:
Principle #6Universality (Multi-functionality)

Data Source

PatentUS20260103693A1Lipase variant
Publication Date: 2026.04.16 KAO CORP
  • US20260103693A1 patent drawing

AI summary

Provided is a lipase mutant with improved heterologous expression. The lipase mutant consists of an amino acid sequence obtained by substituting an amino acid residue at a predetermined position numbered according to SEQ ID NO: 2 with a predetermined amino acid residue in an amino acid sequence of a parent lipase.